Tozorakimab (MEDI3506), another anti–IL-33 antibody, was studied in a phase 2a trial (FRONTIER-2; NCT04212169) involving 148 adults with moderate-to-severe AD. This evidence concerns the gene IL33 and Alzheimer disease.